Takeda on Tuesday announced that it is buying Maverick Therapeutics for as much as $525 million. The deal is a small one, but for R&D chief Andrew Plump, it represents a research and development transformation playing out at the company — and the beginning of the culmination of six years’ work.
“To be honest with you, I think this year is going to be the pinnacle for me,” Plump told STAT when asked about the high point of his time at the company. “This is our inflection year, and this is when all the work that we put in to build the culture, to really create this partnership model and to build a pipeline, this is the year that we and the outside world will start to see how far we’ve come.”
By the end of this year, Plump said, Takeda expects to have filed seven new medicines with regulators the Food and Drug Administration or other regulators around the world, including a drug for non-small cell lung cancer, a vaccine for dengue, and a treatment for a virus that afflicts transplant patients.
About the Author Reprints
